Fragile X Testing in Obstetrics and Gynaecology in Canada

David Chitayat; Philip R. Wyatt; R. Douglas Wilson; Jo Ann Johnson; François Audibert; Victoria Allen; Alain Gagnon; Sylvie Langlois; Claire Blight; Jo Ann Brock; Valerie Désilets; Valerie A. Désilets; Sandra A. Farrell; Michael Geraghty; Tanya Nelson; Sarah M. Nikkel; David Skidmore; Andrea Shugar

doi:10.1016/S1701-2163(16)32949-8

Fragile X Testing in Obstetrics and Gynaecology in Canada

David Chitayat, Philip R. Wyatt, R. Douglas Wilson, Jo Ann Johnson, François Audibert, Victoria Allen, Alain Gagnon, Sylvie Langlois, Claire Blight, Jo Ann Brock, Valerie Désilets, Valerie A. Désilets, Sandra A. Farrell, Michael Geraghty, Tanya Nelson, Sarah M. Nikkel, David Skidmore, Andrea Shugar

Medicine

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

Abstract

Objective: To provide Canadian family physicians, genetic counsellors, medical geneticists, midwives, and obstetrician-gynaecologists with recommendations regarding screening for fragile X in the obstetrical and gynaecological population. Methods: Medline, the Cochrane Library, journals, and textbooks were searched for English-language articles, published between 1966 and March 2008, relating to fragile X testing outcomes. Search terms included fragile X, screening, prenatal testing, pregnancy outcome, premutation, trinucleotide repeats, and ovarian failure. All study types were reviewed. Randomized controlled trial results were considered evidence of the highest quality, followed by results of cohort studies. Key individual studies on which the recommendations are based are referenced. Supporting data for each recommendation are summarized with evaluative comments and references. This document represents an abstraction of the information. Evidence: The quality of evidence reported in this document has been described using the criteria outlined in the report of the Canadian Task Force on Preventive Health Care.

Original language	English
Pages (from-to)	837-841
Number of pages	5
Journal	Journal of Obstetrics and Gynaecology Canada
Volume	30
Issue number	9
DOIs	https://doi.org/10.1016/S1701-2163(16)32949-8
Publication status	Published - 2008

Bibliographical note

Funding Information:
This committee opinion has been prepared by the Genetics Committee of the Society of Obstetricians and Gynaecologists of Canada (SOGC) and the Prenatal Diagnosis Committee of the Canadian College of Medical Geneticists (CCMG) and approved by the Executive of the SOGC and the Board of Directors of the CCMG.

Publisher Copyright:
© 2008 Society of Obstetricians and Gynaecologists of Canada.

ASJC Scopus Subject Areas

Obstetrics and Gynaecology

Access to Document

10.1016/S1701-2163(16)32949-8

Cite this

Chitayat, D., Wyatt, P. R., Wilson, R. D., Johnson, J. A., Audibert, F., Allen, V., Gagnon, A., Langlois, S., Blight, C., Brock, J. A., Désilets, V., Désilets, V. A., Farrell, S. A., Geraghty, M., Nelson, T., Nikkel, S. M., Skidmore, D., & Shugar, A. (2008). Fragile X Testing in Obstetrics and Gynaecology in Canada. Journal of Obstetrics and Gynaecology Canada, 30(9), 837-841. https://doi.org/10.1016/S1701-2163(16)32949-8

Chitayat, D, Wyatt, PR, Wilson, RD, Johnson, JA, Audibert, F, Allen, V, Gagnon, A, Langlois, S, Blight, C, Brock, JA, Désilets, V, Désilets, VA, Farrell, SA, Geraghty, M, Nelson, T, Nikkel, SM, Skidmore, D & Shugar, A 2008, 'Fragile X Testing in Obstetrics and Gynaecology in Canada', Journal of Obstetrics and Gynaecology Canada, vol. 30, no. 9, pp. 837-841. https://doi.org/10.1016/S1701-2163(16)32949-8

@article{66542bcfff8744cd93042d1b0a5bd844,

title = "Fragile X Testing in Obstetrics and Gynaecology in Canada",

abstract = "Objective: To provide Canadian family physicians, genetic counsellors, medical geneticists, midwives, and obstetrician-gynaecologists with recommendations regarding screening for fragile X in the obstetrical and gynaecological population. Methods: Medline, the Cochrane Library, journals, and textbooks were searched for English-language articles, published between 1966 and March 2008, relating to fragile X testing outcomes. Search terms included fragile X, screening, prenatal testing, pregnancy outcome, premutation, trinucleotide repeats, and ovarian failure. All study types were reviewed. Randomized controlled trial results were considered evidence of the highest quality, followed by results of cohort studies. Key individual studies on which the recommendations are based are referenced. Supporting data for each recommendation are summarized with evaluative comments and references. This document represents an abstraction of the information. Evidence: The quality of evidence reported in this document has been described using the criteria outlined in the report of the Canadian Task Force on Preventive Health Care.",

author = "David Chitayat and Wyatt, {Philip R.} and Wilson, {R. Douglas} and Johnson, {Jo Ann} and Fran{\c c}ois Audibert and Victoria Allen and Alain Gagnon and Sylvie Langlois and Claire Blight and Brock, {Jo Ann} and Valerie D{\'e}silets and D{\'e}silets, {Valerie A.} and Farrell, {Sandra A.} and Michael Geraghty and Tanya Nelson and Nikkel, {Sarah M.} and David Skidmore and Andrea Shugar",

note = "Funding Information: This committee opinion has been prepared by the Genetics Committee of the Society of Obstetricians and Gynaecologists of Canada (SOGC) and the Prenatal Diagnosis Committee of the Canadian College of Medical Geneticists (CCMG) and approved by the Executive of the SOGC and the Board of Directors of the CCMG. Publisher Copyright: {\textcopyright} 2008 Society of Obstetricians and Gynaecologists of Canada.",

year = "2008",

doi = "10.1016/S1701-2163(16)32949-8",

language = "English",

volume = "30",

pages = "837--841",

journal = "Journal of Obstetrics and Gynaecology Canada",

issn = "1701-2163",

publisher = "Healthcare & Financial Pub.",

number = "9",

}

TY - JOUR

T1 - Fragile X Testing in Obstetrics and Gynaecology in Canada

AU - Chitayat, David

AU - Wyatt, Philip R.

AU - Wilson, R. Douglas

AU - Johnson, Jo Ann

AU - Audibert, François

AU - Allen, Victoria

AU - Gagnon, Alain

AU - Langlois, Sylvie

AU - Blight, Claire

AU - Brock, Jo Ann

AU - Désilets, Valerie

AU - Désilets, Valerie A.

AU - Farrell, Sandra A.

AU - Geraghty, Michael

AU - Nelson, Tanya

AU - Nikkel, Sarah M.

AU - Skidmore, David

AU - Shugar, Andrea

N1 - Funding Information: This committee opinion has been prepared by the Genetics Committee of the Society of Obstetricians and Gynaecologists of Canada (SOGC) and the Prenatal Diagnosis Committee of the Canadian College of Medical Geneticists (CCMG) and approved by the Executive of the SOGC and the Board of Directors of the CCMG. Publisher Copyright: © 2008 Society of Obstetricians and Gynaecologists of Canada.

PY - 2008

Y1 - 2008

N2 - Objective: To provide Canadian family physicians, genetic counsellors, medical geneticists, midwives, and obstetrician-gynaecologists with recommendations regarding screening for fragile X in the obstetrical and gynaecological population. Methods: Medline, the Cochrane Library, journals, and textbooks were searched for English-language articles, published between 1966 and March 2008, relating to fragile X testing outcomes. Search terms included fragile X, screening, prenatal testing, pregnancy outcome, premutation, trinucleotide repeats, and ovarian failure. All study types were reviewed. Randomized controlled trial results were considered evidence of the highest quality, followed by results of cohort studies. Key individual studies on which the recommendations are based are referenced. Supporting data for each recommendation are summarized with evaluative comments and references. This document represents an abstraction of the information. Evidence: The quality of evidence reported in this document has been described using the criteria outlined in the report of the Canadian Task Force on Preventive Health Care.

AB - Objective: To provide Canadian family physicians, genetic counsellors, medical geneticists, midwives, and obstetrician-gynaecologists with recommendations regarding screening for fragile X in the obstetrical and gynaecological population. Methods: Medline, the Cochrane Library, journals, and textbooks were searched for English-language articles, published between 1966 and March 2008, relating to fragile X testing outcomes. Search terms included fragile X, screening, prenatal testing, pregnancy outcome, premutation, trinucleotide repeats, and ovarian failure. All study types were reviewed. Randomized controlled trial results were considered evidence of the highest quality, followed by results of cohort studies. Key individual studies on which the recommendations are based are referenced. Supporting data for each recommendation are summarized with evaluative comments and references. This document represents an abstraction of the information. Evidence: The quality of evidence reported in this document has been described using the criteria outlined in the report of the Canadian Task Force on Preventive Health Care.

UR - http://www.scopus.com/inward/record.url?scp=58149402674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149402674&partnerID=8YFLogxK

U2 - 10.1016/S1701-2163(16)32949-8

DO - 10.1016/S1701-2163(16)32949-8

M3 - Article

AN - SCOPUS:58149402674

SN - 1701-2163

VL - 30

SP - 837

EP - 841

JO - Journal of Obstetrics and Gynaecology Canada

JF - Journal of Obstetrics and Gynaecology Canada

IS - 9

ER -

Fragile X Testing in Obstetrics and Gynaecology in Canada

Abstract

Bibliographical note

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this